and enhanced potency using pH-activated histidine switching", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol.20, no.9, 1 September 2002 (2002-09-01), pages 908-913, XP002657852, ISSN: 1087-0156, DOI: 10.1038/NBT725 [retrieved on 2002-08-05], WO-A2-2011/111007, US-A1- 2003059937, MAEDA K ET AL: "pH-dependent receptor/ligand dissociation as a determining factor for intracellular sorting of ligands for epidermal growth factor receptors in rat hepatocytes", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol.82, no.1, 18 July 2002 (2002-07-18), pages 71-82, XP004369791, ISSN: 0168-3659, DOI: 10.1016/S0168-3659(02)00126-8, FREDERICK R MAXFIELD & TIMOTHY E MCGRAW: "Endocytic recycling", NATURE REVIEWS MOLECULAR CELL BIOLOGY, NATURE PUBLISHING, GB, vol.5, no.2, 1 February 2004 (2004-02-01), pages 121-132, XP009151548, ISSN: 1471-0072, MEGAN L. MURTAUGH ET AL: "A combinatorial histidine scanning library approach to engineer highly pH-dependent protein switches", PROTEIN SCIENCE, vol. 20, no.9, 1 September 2011 (2011-09-01), pages 1619-1631, XP055011183, ISSN: 0961-8368, DOI: 10.1002/pro.696, IGAWA T ET AL: "Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol.28, no.11, 1 November 2010 (2010-11-01), pages 1203-1207, XP009153598, ISSN: 1087-0156, DOI: 10.1038/NBT.1691, T. IGAWA ET AL: "Reduced elimination of IgG antibodies by engineering the variable region", PROTEIN ENGINEERING DESIGN AND SELECTION, vol.23, no.5, 1 May 2010 (2010-05-01), pages 385-392, XP055003115, ISSN: 1741-0126, DOI: 10.1093/protein/gzq009, IGAWA TOMOYUKI ET AL: "Engineering the variable region of therapeutic IgG antibodies", MABS, LANDES BIOSCIENCE, US, vol.3, no.3, 1 May 2011 (2011-05-01), pages 243-252, XP009153597, ISSN: 1942-0870, ITO W ET AL: "The Hisprobe method: effects of histidine residues introduced into the complementary-determining regions of antibodies on antigen-antibody interactions at different pH values", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol.309, no.1, 1 August 1992 (1992-08-01), pages 85-88, XP008123385, ISSN: 0014-5793, MARTIN W L ET AL: "Crystal Structure at 2.8A of an FcRn/Heterodimeric Fc Complex: Mechanism of pH-Dependent Binding", MOLECULAR CELL, CELL PRESS, CAMBRIDGE, MA, US, vol.7, 1 April 2001 (2001-04-01), pages 867-877, XP003027710, ISSN: 1097-2765, DOI: 10.1016/S1097-2765(01)00230-1, Andrew W Drake ET AL: "Biophysical Consideration for Development of Antibody-Based Therapeutics" In:

"Biophysical Consideration for Development of Antibody-Based Therapeutics", 1 January 2012 (2012-01-01), XP055100977, pages 95-97, * the whole document *, LEE C V ET AL: "Highaffinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol.340, no.5, 23 July 2004 (2004-07-23) , pages 1073-1093, XP002716293, ISSN: 0022-2836,

DOI: 10.1016/J.JMB.2004.05.051, WO-A2-03/105757

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/